These sums, together with additional appropriations that are also specified in the law, were agreed to by FDA, Congress, and industry stakeholders as being essential to high-quality, timely medical device reviews, and to postmarket surveillance and other activities that support reviews.MDUFMA created user fees for the review of several types of medical device applications, specified exclusion of u